M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance
This webinar provided an update and overview on the final M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms guideline including major changes from the draft guideline and FDA’s current bioequivalence (BE) guidance, delineate FDA’s planning on the implementation of M13A, and addressed questions and provided clarifications based on questions/comments received during public consultation of the draft guideline. Timestamps 00:45 – Overview of ICH M13 guideline series 25:32 – FDA’s M13A Implementation for Generic Drug Applications: PSG Revisions to Align with M13A 48:36 – FDA’s M13A Implementation for Generic Drug Applications: Focus on PSG Revisions (Additional M13A and Other Revisions) 01:11:00 – Panel Discussion 01:34:24 – Q&A Panel Discussion 01:50:56 – Closing Remarks Speakers | Panelists: Lei Zhang, PhD Deputy Director Office of Research and Standards (ORS) Office of Generic drugs (OGD) | CDER Nilufer Tampal, PhD Associate Director of Science Quality Office of Bioequivalence (OB) OGD | CDER Myong-Jin (MJ) Kim, PharmD Director Division of Therapeutic Performance II (DTPII) ORS | OGD | CDER Sarah A. Ibrahim, PhD Associate Director for Stakeholder and Global Outreach Engagement OGD | CDER Robert Lionberger, PhD Director ORS | OGD | CDER Partha Roy, PhD Director OB | OGD | CDER Dave Coppersmith, JD Regulatory Counsel Division of Policy Development (DPD) Office of Generic Drug Policy (OGDP) OGD | CDER Qi Zhang, PhD Immediate Release Drug Products Team Leader DTPII | ORS | OGD | CDER Learn more at: https://www.fda.gov/drugs/news-events... ----------------------- FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research. Upcoming Training - https://www.fda.gov/cdersbia SBIA Listserv - https://public.govdelivery.com/accoun... SBIA 2024 Playlist - • 2024 CDER Small Business and Industry Assi... SBIA LinkedIn - / cder-small-business-and-industry-assistance SBIA Training Resources - https://www.fda.gov/cdersbialearn Twitter - / fda_drug_info Email - [email protected] Phone - (301) 796-6707 I (866) 405-5367

Clinical Pharmacology Considerations for Novel Therapeutic Modalities

A Deep Dive: FDA’s Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs

Conversations on Cancer: Patient first = Project Facilitate

Commissioner’s National Priority Voucher (CNPV) Pilot Program Public Hearing

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

FDA Grand Rounds - Clinical Omics Biomarker Discovery and Validation in Precision Medicine

Pharmacovigilance in Practice From Safety Signals to Regulatory Action 1080

FDA Direct: The Power of Real-Time Clinical Trials

CDRH - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Navigating First ICH Generic Drug Draft Guideline M13A Bioequivalence for IR Solid Oral Dosage Forms

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

Advancing Real-Time Clinical Trials

VRBPAC -- May 28 Meeting

CDER - REdI Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products

Oncology Nurses - The Frontliners in Oncology

Advancing Smoking Cessation: FDA and NIH Priorities

FDA Clinical Investigator Training Course (CITC) 2024 (Day 1 of 3)

Know Your Nutrition

Best Practices for Conducting Bioequivalence Studies (16of27) Generic Drugs Forum 2018

